Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer

Philip Shie, Roberto Cardarelli, David Brandon, William Erdman, Nashila Abdulrahim

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

PURPOSE: To evaluate the diagnostic properties of FDG-PET and bone scintigraphy in the detection of osseous metastases in patients with breast cancer. MATERIALS AND METHODS: Studies evaluating the diagnostic accuracy of FDG-PET and bone scintigraphy in the diagnosis of osseous metastasis were systematically searched for in the MEDLINE, CINAHL, and EBM Review databases from January 1995 to November 2006. Two reviewers independently abstracted data including research design, sample size, imaging technique and technical characteristics, reference standard, method of image interpretation, and totals of true positives, false positives, true negatives, and false negatives. Per-patient and per-lesion pooled sensitivity and specificity, and area under summary receiver operating characteristic curves were calculated using Meta-Test software. RESULTS: The pooled patient-based sensitivity for FDG-PET was 81% (95% CI: 70%-89%), specificity was 93% (95% CI: 84%-97%), and the area under the curve (AUC) was 0.08. The pooled sensitivity of bone scan was 78% (95% CI: 67%-86%), specificity was 79% (95% CI: 40%-95%), and the AUC was 0.43. The pooled lesion-based sensitivity for FDG-PET was 69% (95% CI: 28%-93%), specificity was 98% (95% CI: 87%-100%), and the AUC was 0.09. The pooled sensitivity for bone scan was 88% (95% CI: 82%-92%), specificity was 87% (95% CI: 29%-99%), and the AUC was 0.81. CONCLUSIONS: It remains inconclusive whether FDG-PET or bone scintigraphy is superior in detecting osseous metastasis from breast cancer. However, FDG-PET does have a higher specificity and may better serve as a confirmatory test than bone scintigraphy and used to monitor response to therapy.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalClinical Nuclear Medicine
Volume33
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Fluorodeoxyglucose F18
Radionuclide Imaging
Positron-Emission Tomography
Meta-Analysis
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Area Under Curve
MEDLINE
ROC Curve
Sample Size
Research Design
Software
Databases
Sensitivity and Specificity

Keywords

  • Bone metastases
  • Bone scan
  • Bone scintigraphy
  • Breast cancer
  • FDGPET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Meta-analysis : Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. / Shie, Philip; Cardarelli, Roberto; Brandon, David; Erdman, William; Abdulrahim, Nashila.

In: Clinical Nuclear Medicine, Vol. 33, No. 2, 02.2008, p. 97-101.

Research output: Contribution to journalArticle

Shie, Philip ; Cardarelli, Roberto ; Brandon, David ; Erdman, William ; Abdulrahim, Nashila. / Meta-analysis : Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. In: Clinical Nuclear Medicine. 2008 ; Vol. 33, No. 2. pp. 97-101.
@article{a3abfde4288e4a56926815e69057da7b,
title = "Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer",
abstract = "PURPOSE: To evaluate the diagnostic properties of FDG-PET and bone scintigraphy in the detection of osseous metastases in patients with breast cancer. MATERIALS AND METHODS: Studies evaluating the diagnostic accuracy of FDG-PET and bone scintigraphy in the diagnosis of osseous metastasis were systematically searched for in the MEDLINE, CINAHL, and EBM Review databases from January 1995 to November 2006. Two reviewers independently abstracted data including research design, sample size, imaging technique and technical characteristics, reference standard, method of image interpretation, and totals of true positives, false positives, true negatives, and false negatives. Per-patient and per-lesion pooled sensitivity and specificity, and area under summary receiver operating characteristic curves were calculated using Meta-Test software. RESULTS: The pooled patient-based sensitivity for FDG-PET was 81{\%} (95{\%} CI: 70{\%}-89{\%}), specificity was 93{\%} (95{\%} CI: 84{\%}-97{\%}), and the area under the curve (AUC) was 0.08. The pooled sensitivity of bone scan was 78{\%} (95{\%} CI: 67{\%}-86{\%}), specificity was 79{\%} (95{\%} CI: 40{\%}-95{\%}), and the AUC was 0.43. The pooled lesion-based sensitivity for FDG-PET was 69{\%} (95{\%} CI: 28{\%}-93{\%}), specificity was 98{\%} (95{\%} CI: 87{\%}-100{\%}), and the AUC was 0.09. The pooled sensitivity for bone scan was 88{\%} (95{\%} CI: 82{\%}-92{\%}), specificity was 87{\%} (95{\%} CI: 29{\%}-99{\%}), and the AUC was 0.81. CONCLUSIONS: It remains inconclusive whether FDG-PET or bone scintigraphy is superior in detecting osseous metastasis from breast cancer. However, FDG-PET does have a higher specificity and may better serve as a confirmatory test than bone scintigraphy and used to monitor response to therapy.",
keywords = "Bone metastases, Bone scan, Bone scintigraphy, Breast cancer, FDGPET",
author = "Philip Shie and Roberto Cardarelli and David Brandon and William Erdman and Nashila Abdulrahim",
year = "2008",
month = "2",
doi = "10.1097/RLU.0b013e31815f23b7",
language = "English (US)",
volume = "33",
pages = "97--101",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Meta-analysis

T2 - Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer

AU - Shie, Philip

AU - Cardarelli, Roberto

AU - Brandon, David

AU - Erdman, William

AU - Abdulrahim, Nashila

PY - 2008/2

Y1 - 2008/2

N2 - PURPOSE: To evaluate the diagnostic properties of FDG-PET and bone scintigraphy in the detection of osseous metastases in patients with breast cancer. MATERIALS AND METHODS: Studies evaluating the diagnostic accuracy of FDG-PET and bone scintigraphy in the diagnosis of osseous metastasis were systematically searched for in the MEDLINE, CINAHL, and EBM Review databases from January 1995 to November 2006. Two reviewers independently abstracted data including research design, sample size, imaging technique and technical characteristics, reference standard, method of image interpretation, and totals of true positives, false positives, true negatives, and false negatives. Per-patient and per-lesion pooled sensitivity and specificity, and area under summary receiver operating characteristic curves were calculated using Meta-Test software. RESULTS: The pooled patient-based sensitivity for FDG-PET was 81% (95% CI: 70%-89%), specificity was 93% (95% CI: 84%-97%), and the area under the curve (AUC) was 0.08. The pooled sensitivity of bone scan was 78% (95% CI: 67%-86%), specificity was 79% (95% CI: 40%-95%), and the AUC was 0.43. The pooled lesion-based sensitivity for FDG-PET was 69% (95% CI: 28%-93%), specificity was 98% (95% CI: 87%-100%), and the AUC was 0.09. The pooled sensitivity for bone scan was 88% (95% CI: 82%-92%), specificity was 87% (95% CI: 29%-99%), and the AUC was 0.81. CONCLUSIONS: It remains inconclusive whether FDG-PET or bone scintigraphy is superior in detecting osseous metastasis from breast cancer. However, FDG-PET does have a higher specificity and may better serve as a confirmatory test than bone scintigraphy and used to monitor response to therapy.

AB - PURPOSE: To evaluate the diagnostic properties of FDG-PET and bone scintigraphy in the detection of osseous metastases in patients with breast cancer. MATERIALS AND METHODS: Studies evaluating the diagnostic accuracy of FDG-PET and bone scintigraphy in the diagnosis of osseous metastasis were systematically searched for in the MEDLINE, CINAHL, and EBM Review databases from January 1995 to November 2006. Two reviewers independently abstracted data including research design, sample size, imaging technique and technical characteristics, reference standard, method of image interpretation, and totals of true positives, false positives, true negatives, and false negatives. Per-patient and per-lesion pooled sensitivity and specificity, and area under summary receiver operating characteristic curves were calculated using Meta-Test software. RESULTS: The pooled patient-based sensitivity for FDG-PET was 81% (95% CI: 70%-89%), specificity was 93% (95% CI: 84%-97%), and the area under the curve (AUC) was 0.08. The pooled sensitivity of bone scan was 78% (95% CI: 67%-86%), specificity was 79% (95% CI: 40%-95%), and the AUC was 0.43. The pooled lesion-based sensitivity for FDG-PET was 69% (95% CI: 28%-93%), specificity was 98% (95% CI: 87%-100%), and the AUC was 0.09. The pooled sensitivity for bone scan was 88% (95% CI: 82%-92%), specificity was 87% (95% CI: 29%-99%), and the AUC was 0.81. CONCLUSIONS: It remains inconclusive whether FDG-PET or bone scintigraphy is superior in detecting osseous metastasis from breast cancer. However, FDG-PET does have a higher specificity and may better serve as a confirmatory test than bone scintigraphy and used to monitor response to therapy.

KW - Bone metastases

KW - Bone scan

KW - Bone scintigraphy

KW - Breast cancer

KW - FDGPET

UR - http://www.scopus.com/inward/record.url?scp=38349144331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349144331&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e31815f23b7

DO - 10.1097/RLU.0b013e31815f23b7

M3 - Article

C2 - 18209527

AN - SCOPUS:38349144331

VL - 33

SP - 97

EP - 101

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -